Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Laura Huppert, MD, discusses efficacy and safety outcomes from the phase 3 ASCENT-04 trial, which compared the combination of ...

Please provide your email address to receive an email when new articles are posted on . Sacituzumab govitecan did not improve PFS in HR-positive, HER2-negative breast cancer after endocrine therapy.

Please provide your email address to receive an email when new articles are posted on . Results of the trial, which compared PFS among patients with hormone receptor-positive, HER2-negative breast ...

SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for ...

Highlights in ER-positive breast cancer from SABCS 2025 include key metastatic and early-stage trial results from AMBRE, ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Share on Pinterest Cannabis derivatives may lead to new treatments for ovarian cancer. Image Credit: Bloomberg Creative Photos/Getty Images Early lab research shows that two cannabis compounds, THC ...

Scientists have discovered that key compounds from cannabis—CBD and THC—show surprisingly strong effects against ovarian cancer cells. Used together, they slow cell growth, reduce colony formation, ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

A digital illustration of semaglutide binding to a receptor. ProLynx is working to extend the half-life of semaglutide, shown here in a digital illustration. Credit: Science Source The biotechnology ...